Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800. The company is set for strong growth over the next 3 years. The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).
Tata Communications Q1 Results: Cons PAT falls 43% YoY to Rs 190 crore, revenue up 7%
Tata Communications reported a 43% YoY drop in Q1FY26 net profit at Rs 190 crore. Revenue rose 7% to Rs 5,960 crore. Sequentially, profit plunged